2002/2003 fiscal year nine months. EGIS Pharmaceuticals Ltd.

Transcription

1 2002/2003 fiscal year nine months EGIS Pharmaceuticals Ltd.

2 Contents Main characteristics of the 2003 April-June period Data of the 3 quarter period development of costs comparison of quarterly results sales development in main markets development of the commercial network sales revenue on leading products main components of the financial profit forex contracts

3 Change relative to the comparative period % Q1 Q2 Q3 Total Domestic sales Export sales in HUF Net sales Export sales in USD Russia + other CIS countries Eastern Europe West - finished products (FP) active pharm. ingredients (API)

4 Sales revenues (3rd quarter) Apr.-Jun. Apr.-Jun. Change % Domestic mkt HUFmln 5,806 5,923-2 Export USD thousand 38,771 30, Russia + CIS 14,060 10, Eastern Europe 11,099 8, West FP 6,246 3, API 7,366 7,736-5 Export HUFmln 8,601 7,985 8 Exchange rate

5 Domestic market HUF million Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

6 Russia + other C.I.S. mkts USD thousand Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

7 Eastern Europe Eastern Europe USD thousand Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

8 Sales of finished products in Western mkts USD thousand Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

9 API and others USD thousand Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

10 Direct cost development Direct cost development (3rd quarter) HUF million Apr.-Jun. Apr.-Jun. Change % Production costs 4,592 4,380 5 Operating costs of plants 1,311 1,316 0 Total 5,903 5,696 4 as % of sales Volume growth 9%

11 Main data (3rd quarter) HUF million Apr.-Jun Apr.-Jun Change % Net sales 14,407 13,908 4 Directs costs 5,903 5,696 4 Margin 8,504 8,212 4 Indirect costs 6,308 5, Other income and expenses Operating profit 2,048 2, as % of sales 14 17

12 Operating profit HUF million Oct-Dec Jan-Mar Apr-Jun July-Sep / / / / /2003

13 Main data II. (3rd quarter) HUF million Apr.-Jun. Apr.-Jun Financial profit Extraordinary profit 3-23 Change % Profit before tax 1,957 2, Profit after tax 1,723 2,286-25

14 Comparison of nine month results

15 Main data Main data (nine months) HUF million Oct Jun Oct Jun. Change % Sales 42,544 41,618 2 Direct costs 18,802 17,578 7 Margin 23,742 24,040-1 Indirect costs 17,761 16, Other income and ,084 expenditure Operating profit 4,983 6, as % of sales 12 16

16 Main data II. (nine months) HUF million Oct Oct Jun Jun. Financial results Extraordinary profit Change % Profit before tax 5,097 6, Profit after tax 4,486 5, Headcount (people) 2,676 2, ple CAPEX and investment 5,664 4,715 20

17 Export (nine months) USD thousand Oct Jun Oct Jun. Change % Russia + CIS 34,058 28, Eastern Europe 32,840 25, West FP 14,996 10, API 29,191 30,382-4 Total export 111,085 94, Export (in HUFmln) 25,373 25,977-2 Exchange rate

18 Sales in Eastern Europe (+Vietnam) (nine months) USD thousand Oct Oct.- Change Jun Jun. % Poland 13,737 10, Czech Republic 6,302 4, Slovakia 5,032 3, Romania 4,603 3, Bulgaria 1, Vietnam 1,783 1, Total 32,840 25,390 29

19 The commercial network of EGIS Ltd. Sept.30, 2002 people June 30, 2003 people Domestic market Export markets Total 981 1,084 From Export EGIS Budapest Russia+CIS Eastern Europe Offices in Western countries 93 66

20 Direct cost development Direct cost development (nine months) HUF million Oct Jun Oct Jun. Change % Production costs 14,477 13,573 7 Operating costs of plants 4,325 4,005 8 Total 18,802 17,578 7 as % of sales Volume growth 9%

21 Indirect cost development Indirect cost development (nine months) Ft million Oct Jun Oct Jun. Change % Sales costs 9,095 8,427 8 as % of sales R&D costs 3,296 2, as % of sales Admin. costs 3,454 2, Other general costs 1,916 1,791 7

22 Sales on leading product Sales on leading product (nine months) Product Sales (HUF million) Change % Methyldopa 3, Coverex 2, Nitromint 2,389 3 Suprastin 2, Betaloc 1, Bioparox 1,740 5 Levomepromazin 1,591-1 Lucetam 1, Allopurinol 1, Betadine 1,368-13

23 Sales of best growing products Sales of best growing products (nine months) Product Sales (HUF million) Change (HUF million) Lucetam 1, Thiofestermet Betaloc 1, Frontin 1, Cardilopin Floxet Coverex 2, Adexor 1, Tamoxifen Kaldyum

24 Leading products in the domestic mkt Leading products in the domestic mkt. (nine months) Product Sales (HUF million) Change % Coverex 2, Nitromint 1,430 8 Adexor 1, Betaloc Dormicum Andaxin Cardilopin Frontin Vitamin C Tenaxum

25 Best growing prod in domestic mkt. (nine months) Product Sales (HUF million) Change (HUF million) Cardilopin Coverex 2, Adexor 1, Talliton Betaloc Frontin Stimuloton Tenaxum Nitromint 1,

26 Main components of the financial profit HUF million 2002.Oct June 2003 Apr.-Jun. Net interest income Dividends Currency rate difference of receivables and liabilities Forex contracts Other items Total

27 Hedge contracts Results of closed contracts (Oct.-Jun): HUF 266 mln Open contracts: July fwd: HUF 244 / EUR option : 1.10 August option and or Knock-out option (243.60/1.12) September fwd and option or Knock-out option (1.14) October fwd 256 November fwd 257 December fwd 263 January fwd 272